Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

Summary

The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are: 1. Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion 2. Can SNK01 administration improve cognitive assessment scores and biomarkers

Timeline

Start

2023-11-21

Primary completion

2026-12

Completion

2027-06

Drugs

Indications